Linkedm People v
`
`DAVlD
`
`MOTTOLA, PhD
`
`Ct
`
`Join now
`
`DAVID’S public profile badge
`Include tliis Linkedln profile on other
`
`VlCC moment, Clinical
`DCVCiDDMCN a! Gossamer Blfl
`
`websites . DAVlD MOTTOLA, PhD
`
`"'
`
`,
`
`Chapel Hill
`| University of North Carolina at
`
`DAVID MOTTO LA. PhD
`Vice President, Clinical Development at Gossamer Bio
`San Diego, California, United States - 255 connections
`on
`to Connect
`
`flwnen signing a you caaciiause in let’.‘ we profile in plvate lTCde
`
`
`
`University of North Carolina at
`Chapel H'”
`
`Linkedfifi
`
`9‘" profile badges
`
`About
`PRODUCT DEVELOPMENTO CORPORATE STRATEGY # LlCENSlNG/BUSINESS DEVELOPMENT
`
`An agile, solution-oriented senior-level Research 84 Development leader, he has a track record of
`career achievements that spans the full scope of product development, business development,
`corporate strategy, and financial management for biopharmaceutical companies.
`
`He has a reputation as a quality deliverables champion with strong interpersonal skills, a nigh level of
`personal initiative and who thinks analytically and proactively to achieve organizational goals in both
`start-up and established organizations. He is known for his keen insights regarding technical
`execution of product developments and portfolio management. As an innovator, he has excellent
`problem-solving abilities to readily address emerging challenges, while maintaining rigorous quality
`standards and compliance With regulatory requirements. His broad executive leadership experience
`provides acumens to drive company growth and success.
`
`In addition, he has provided expert consulting and advisory services to small— and medium-sized
`biopharma companies to facilitate regulatory filings, surmount regulatory challenges and define
`clinical strategies and plans.
`
`A few representative examples of his successes related to organizational leadership, product
`development, and business strategy and partnership development include:
`\lGuided United Therapeutics‘ iUT) clinical affairs and product development from start-up with zero
`revenue to ~$900M in revenue.
`\IDevelcped and advanced multiple products at UT to drive company from no approved product to a
`four approved-product portfolio, with a corresponding 1600% revenue increase in 10 years.
`\ICreated and advanced strategies to develop GeneEiology's lead product, raise capital and financial
`bootstrapping, and cultivate relationships with key partners.
`\lGuided 5 NBA approvals and 3 Orphan Drug Designation approvals with the FDA
`Demonstrated RGtD, Business 8t Leadership Strengths:
`RESEARCH 8: DEVELOPMENT (RSiD) | SClENTIFIC STRATEGY i CLlNICAL OPERATlONS & SClENCESI
`DRUG PORTFOLIO MANAGEMENT | QUALITY Si PROCESS IMPROVEMENT | TEAM BUILDING 8i
`ENGAGEMENT | OUT-LICENSlNG |
`|N>LlCENSlNG i FDA REGlSTRATION 81 APPROVAL
`
`Activity
`
`
`
`Nice article
`Liked by DAVID MOTTOLA. PhD
`
`#6038 is proud to support #CCAwarenessWeek & our partners at
`@CrohnsColitian by continuing our #ThreadZPatients campaign through
`to Dec, 7th!...
`Liked by DAVID MDTTOLA, PhD
`
`"to listen carefully to the wisdom of patients" -- Sandy, Director of New
`Product Planning #ThreadZPatients #phawarenessmonth #phaware
`PHAWAREm
`Liked by DAVID MOTTOLA. PhD
`
`gn in to see all acti
`
`ty
`
`Education
`
`University of North Carolina at Chapel Hill
`Doctor of Philosophy (PhD) i Pharmacology
`
`State University of New York at Bing hamton
`Bachelor oI Science (BS) , Biology/Biological Sciences, General
`
`
`
`View DAVID'S full profile
`CD See who you know in common
`'El Get introduced
`88. Contact DAVlD directly
`
`Sign in to \l wfull pr
`
`Linker-Jim oznzi Ami" Accesslalllty
`
`Leer/Agreement
`
`PilL'aCyPallci,
`
`CookiePallcy Capf’lgttPollcy Branch-llcy
`
`SLESICUHUDiS
`
`ComniunityGuidelines Languagev
`
`
`
`